Shots:

• New Brunswick joins British Columbia and Alberta in implementing a “switch” policy that changes coverage for specific biologic medicines
• Patients switching from reference biologics to biosimilar versions will continue receiving safe- effective treatment and will enable to save millions of dollars once implemented
• Sandoz is committed to supporting patients- their HCPs- and the New Brunswick Government with high quality biosimilar medicines and experienced- comprehensive patient support programs

  Ref: Sandoz | Image: Sandoz